NEW YORK (GenomeWeb) – Twist Bioscience announced today that it has signed a non-exclusive agreement with Synbio Technologies, a biotech company that focuses on DNA technology and applications.
The companies will work in tandem to provide customers worldwide with access to genes up to 70 kilobases in length.
"By leveraging our collective expertise in next-generation gene synthesis, we believe we will see new uses of DNA to improve the diagnosis and treatment of diseases," Synbio CEO Ping Yang said in a statement.
Twist will assemble synthetic DNA strands up to 3.2 kilobases in length, with which Synbio will then create genes up to 70 kilobases in length. Financial terms of the agreement were not disclosed.
According to Twist CEO Emily Leproust, the partnership will reinforce a geographic reach for the company's synthetic DNA in Asia, establishing a connection in the Chinese marketplace.
Earlier this year, Twist Bioscience raised $27 million in venture capital, and is currently involved in a lawsuit with Agilent Technologies, which claims that Twist stole genomics technology.